Trial Profile
A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2013
Price :
$35
*
At a glance
- Drugs Tenofovir (Primary) ; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors CONRAD
- 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
- 01 Nov 2010 Status changed from recruiting to completed.
- 02 Oct 2009 New trial record